• In a research study conducted in the USA, a computer model run by researchers reviews the potential benefits and harms of estrogen-blocking drugs that are given to breast cancer suspects.

  • This test was designed to measure the effects of screening and treatment on breast cancer incidence and mortality.

  • The research study will help doctors decide on the usage of estrogen-blocking drugs in clinical practice. 
  • According to the Centers for Disease Control and Prevention (CDC), women with inherited BRCA1 and BRCA2 gene mutations have a potential risk of getting breast cancer. 
  • An estrogen-blocking drug was found effective in lowering the threat of invasive breast cancer by 40% and the risk of death by 57% in women.

  • It was found that drugs like Tamoxifen and Exemestane can lower the occurrence of ER-positive (Estrogen-Receptor +) breast cancer by 30-50% in healthy women who are at increased risk of breast cancer.

  • The Journal of Clinical Oncology published this study's results. The study was held on an existing breast cancer computer model called the Spectrum/Georgetown-Einstein (G-E) model. 
  • The pros and cons of the estrogen-blocking drug vary among individuals and are dependent on factors such as age, prior biopsy, and genetic history of breast cancer.
  • Dr. Kathy D. Miller, professor of oncology and medicine at the Indiana University School of Medicine, said, "Many physicians and patients underestimate the benefit and overestimate the side effects of drugs.

Source - Medical News Today

To Know more about the Best Cancer Treatment Hospitals Worldwide: